SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02081378

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.

NCT02081378 Chronic Myelogenous Leukemia Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
MeSH:Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Philadelphia Chromosome
HPO:Chronic myelogenous leukemia Leukemia Lymphoid leukemia Myeloid leukemia

5 Interventions

Name: ABL001

Description: ABL001 will be administered orally in a dose escalation schedule.
Type: Drug
Group Labels: 1

ABL001 in CML patients

Name: ABL001 + Nilotinib

Description: ABL001 and Nilotinib will be administered orally in CML patients
Type: Drug
Group Labels: 1

ABL001+Nilotinib in CML patients

Name: ABL001

Description: ABL001 will be administered orally in Ph+ ALL patients
Type: Drug
Group Labels: 1

ABL001 in Ph+ ALL patients

Name: ABL001+imatinib

Description: ABL001 and imatinib will be administered orally in CML patients
Type: Drug
Group Labels: 1

ABL001+Imatinib in CML patients

Name: ABL001+dasatinib

Description: ABL001+dasatinib will be administered orally in CML patients
Type: Drug
Group Labels: 1

ABL001+dasatinib in CML patients


Primary Outcomes

Description: Determine the MTD and/or RDE of ABL001 as single agent in CML and Ph+ ALL, and in combination with either nilotinib or imatinib or dasatinib in CML patients

Measure: Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatment

Time: First Cycle is 28 days

Secondary Outcomes

Measure: Hematologic Response

Time: At screening and first day of cycle 2 and 3 and every 12 weeks afterwards

Measure: Cytogenetic response

Time: at screening or when a patient's BCR-ABL ratio has risen to >1%

Measure: BCR-ABL transcript level

Time: At screening and first day of cycle 2 and 3 and every 12 weeks afterwards

Measure: Cmax of ABL001 as measured in plasma

Time: Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.

Measure: Cmin of ABL001 as measured in plasma

Time: Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.

Measure: AUCinf of ABL001 as measured in plasma

Time: Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.

Measure: AUClast of ABL001 as measured in plasma

Time: Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.

Measure: AUCtau of ABL001 as measured in plasma

Time: Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.

Measure: T1/2 of ABL001 as measured in plasma

Time: Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.

Measure: Adverse events

Time: Collected from screening visit through post-treatment follow-up period

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 T315I

Inclusion Criteria: For CML patients either: - a. Patients with Ph+ CML in chronic or accelerated phase who were previously treated with at least two different tyrosine kinase inhibitors prior to study entry and are relapsed, refractory to or intolerant of TKIs as determined by investigators or - b. Patients with CML in chronic or accelerated phase who exhibit relapsed disease associated with the presence of the T315I "gatekeeper mutation" after at least one TKI are also eligible provided that no other effective therapy exists For ALL and CML-BP patients: - Patients with CML BP or Ph+ ALL who have a cytopathologically confirmed diagnosis and are relapsed or refractory to at least one prior TKI or intolerant of TKIs. --- T315I ---

At least four weeks must have elapsed since prophylactic CNS irradiation given as part of a front-line therapy regimen for ALL - Major surgery within 2 weeks before the first dose of study treatment Other protocol-defined inclusion/exclusion criteria may apply Inclusion Criteria: For CML patients either: - a. Patients with Ph+ CML in chronic or accelerated phase who were previously treated with at least two different tyrosine kinase inhibitors prior to study entry and are relapsed, refractory to or intolerant of TKIs as determined by investigators or - b. Patients with CML in chronic or accelerated phase who exhibit relapsed disease associated with the presence of the T315I "gatekeeper mutation" after at least one TKI are also eligible provided that no other effective therapy exists For ALL and CML-BP patients: - Patients with CML BP or Ph+ ALL who have a cytopathologically confirmed diagnosis and are relapsed or refractory to at least one prior TKI or intolerant of TKIs. --- T315I ---



HPO Nodes


HPO: